Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

Science. 1994 May 13;264(5161):961-5. doi: 10.1126/science.7513904.

Abstract

Many tumors express tumor-specific antigens capable of being presented to CD8+ T cells by major histocompatibility complex (MHC) class I molecules. Antigen presentation models predict that the tumor cell itself should present these antigens to T cells. However, when conditions for the priming of tumor-specific responses were examined in mice, no detectable presentation of MHC class I-restricted tumor antigens by the tumor itself was found. Rather, tumor antigens were exclusively presented by host bone marrow-derived cells. Thus, MHC class I-restricted antigens are efficiently transferred in vivo to bone marrow-derived antigen-presenting cells, which suggests that human leukocyte antigen matching may be less critical in the application of tumor vaccines than previously thought.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antigen-Presenting Cells / immunology*
  • Antigens, Neoplasm / immunology*
  • Bone Marrow / immunology
  • Bone Marrow Cells
  • Colonic Neoplasms / immunology
  • Epitopes
  • Female
  • Granulocyte-Macrophage Colony-Stimulating Factor / genetics
  • Granulocyte-Macrophage Colony-Stimulating Factor / immunology
  • H-2 Antigens / immunology
  • Histocompatibility Antigens Class I / immunology*
  • Melanoma, Experimental / immunology
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Nucleocapsid Proteins
  • Nucleoproteins*
  • T-Lymphocytes, Cytotoxic / immunology*
  • Tumor Cells, Cultured
  • Viral Core Proteins / immunology

Substances

  • Antigens, Neoplasm
  • Epitopes
  • H-2 Antigens
  • Histocompatibility Antigens Class I
  • Nucleocapsid Proteins
  • Nucleoproteins
  • Viral Core Proteins
  • Granulocyte-Macrophage Colony-Stimulating Factor